How Novo’s Acquisition Of Catalent Cleared European Regulators

 
• By Francesca Bruce

Now that one of the most controversial pharma M&As of 2024 has closed, the Pink Sheet looks at whether overtures to concerned customers and extended prenotification discussions helped Novo and Catalent seal the deal.

Pink Sheet Perspectives 2025
Novo's acquisition of Catalent was formalized at the end of 2024 (Shutterstock)

More from Manufacturing

More from North America